Journal Mobile Options
Table of Contents
Vol. 85, No. 4, 2012
Issue release date: June 2012
Digestion 2012;85:295–301

Clinical Features and Management of Parastomal Pyoderma Gangrenosum in Inflammatory Bowel Disease

Uchino M. · Ikeuchi H. · Matsuoka H. · Bando T. · Takahashi Y. · Takesue Y. · Matsumoto T. · Tomita N.
aDepartment of Surgery, bDivision of Infection Control and Prevention, and cDivision of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Pyoderma gangrenosum (PG) is often associated with inflammatory bowel disease even after bowel surgery, but it remains an extremely rare pathology. The purpose of this study was to investigate the clinical features and treatment of PG and to consider proper management for peristomal PG. Methods: Demographic data for patients who underwent colorectal surgery with ostomy creation at Hyogo College of Medicine between July 2007 and July 2011 were prospectively collected. The main outcome measures were postoperative occurrence of peristomal PG by type: explosive and rapidly spreading type (type R) and indolent and gradually spreading type (type G). Results: Overall prevalence was 11/738 (1.5%), with type R in 5 patients and type G in 6. Type R and type G were significantly more common in ulcerative colitis and Crohn’s disease, respectively (p = 0.01). Type R developed within 6 days after surgery. Type G developed a mean of 52 days after surgery. Complete healing required a long time in both types, with means of 69 days for type R and 48 days for type G. Conclusion: Although peristomal PG was a rare complication after surgery, differences in the development of PG were observed between ulcerative colitis and Crohn’s disease. Careful observation and knowledge of PG are needed.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Greenstein AJ, Janowitz HD, Sachar DB: The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976;55:401–412.
  2. Menachem Y, Gotsman I: Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. Isr Med Assoc J 2004;6:88–90.
  3. Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G: Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009;29:1008–1017.

    External Resources

  4. Levitt MD, Ritchie JK, Lennard-Jones JE, Phillips RK: Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 1991;78:676–678.
  5. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG: CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 1992;13:606–608.
  6. Truelove SC, Witts LJ: Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ 1955;2:1041–1048.
  7. Winship DH, Summers RW, Singleton JW, Best WR, Becktel JM, Lenk LF, Kern F Jr: National Cooperative Crohn’s Disease Study: study design and conduct of the study. Gastroenterology 1979;77:829–842.
  8. Last M, Fazio VW, Lavery I, Jagelman D: Conservative management of paraileostomy ulcers in patients with Crohn’s disease. Dis Colon Rectum 1984;27:779–786.
  9. Hughes AP, Jackson JM, Callen JP: Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000;284:1546–1548.
  10. Marzano AV, Cugno M, Trevisan V, Fanoni D, Venegoni L, Berti E, Crosti C: Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin disease. Clin Exp Immunol 2010;162:100–107.
  11. Wollina U: Pyoderma gangrenosum – a review. Orphanet J Rare Dis 2007;2:19.

    External Resources

  12. Tay YK, Friednash M, Aeling JL: Acute pyoderma gangrenosum does not require surgical therapy. Arch Fam Med 1998;7:377–380.
  13. Ayestaray B, Dudrap E, Chartaux E, Verdier E, Joly P: Necrotizing pyoderma gangrenosum: an unusual differential diagnosis of necrotizing fasciitis. J Plast Reconstr Aesthet Surg 2010;63:e655–e658.

    External Resources

  14. Bisarya K, Azzopardi MS, Lye G, Drew PJ: Necrotizing fasciitis versus pyoderma gangrenosum: securing the correct diagnosis! A case report and literature review. J Plast Surg 2011;11:218–227.
  15. Ayestaray B, Dudrap E, Chartaux E, Verdier E, Joly P: Necrotizing pyoderma gangrenosum: an usual differential diagnosis of necrotizing fasciitis. J Plast Reconstr Aesthet Surg 2010;63:e655–e658.

    External Resources

  16. Williams S: Recognizing peristomal pyoderma gangrenosum. J Enterostomal Ther 1984;11:77–79.
  17. Wolfsen HC, Brubacher LL, Ng CG, Kayne AL, Kozarek RA: Refractory parastomal ulcers: a multidisciplinary approach. J Clin Gastroenterol 1990;12:651–655.
  18. Cairns BA, Herbst CA, Sartor BR, Briggaman RA, Koruda MJ: Peristomal pyoderma gangrenosum and inflammatory bowel disease. Arch Surg 1994;129:769–772.
  19. Funayama Y, Kumagai E, Takahashi K, Fukushima K, Sasaki I: Early diagnosis and early corticosteroid administration improves healing of peristomal pyoderma gangrenosum in inflammatory bowel disease. Dis Colon Rectum 2009;52:311–314.

    External Resources

  20. Uchino M, Ikeuchi H, Bando T, Matsuoka H, Hirata A, Takahashi Y, Takesue Y, Inoue S, Tomita N: Diffuse gastroduodenitis and enteritis associated with ulcerative colitis and concomitant cytomegalovirus reactivation after total colectomy: report of a case. Surg Today 2012, in press.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50